English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editor,  The Editorial by Hage and Iskandrian1 regarding “Serious complications associated with regadenoson administration for myocardial perfusion imaging: A commentary” (September/October 2014 issue) includes a table as a guide for serious complications associated with regadenoson administration. In the table, the authors reported whether or not each listed event occurs with exercise and/or adenosine and that seizures have not been reported with adenosine. Astellas has received spontaneous post-marketing reports of seizures in patients administered adenosine, and the package insert for Adenoscan® was updated in 2005 to reflect these reports. The current package insert includes “seizure” in the Warnings section.2 In addition, there is one published case report of bradyasystole and seizures associated with the use of adenosine to terminate supraventricular tachycardia.3 Astellas would like to clarify that seizures can occur following the administration of adenosine, and prescribers should be aware of this risk and prepared to treat if necessary.2 The use of methylxanthines (e.g., caffeine, aminophylline, and theophylline) is not recommended in patients who experience seizures in association with adenosine and regadenoson.2